Adem Albayrak

Chief Data Officer at Alzheo

Speaker

Adem Albayrak is the Chief Data Officer of Alzheon, a Phase 3 company targeting Early Alzheimer’s disease in patients with the highest genetic risk for disease, APOE4 homozygotes. Adem has an almost 2 decade-long career in data-centric precision medicine and clinical research across industry and academia. Previously, Adem was the Senior Vice President for Technology in Health Catalyst’s Life Sciences Business, tying together data, analytics, and product development to drive innovations through the use of real-world data towards retrospective studies, real-time monitoring of COVID-19 in collaboration with the FDA and other organizations, and identifying sites and patients to optimize clinical trial recruitment. Prior to Health Catalyst, he oversaw the genomics data pipeline at Dana-Farber Cancer Institute that enabled clinical research and translational medicine; supported researchers in bioinformatics and analytics projects; and led product management for the enterprise that included software for IRB-approved research data delivery, clinical trial matching, and real world data curation. Previously, Adem led product management at BIOBASE, where he launched a pharmacogenomics data product, which was acquired by Qiagen. Additionally, Ademspearheaded software product development at Knome, where he built and supported products in variant and gene pathway analysis.

Adem served as a Sergeant in the reserves of the United States Marine Corps. He earned his B.S. and M.S. in Computer Science with a bioinformatics focus from the University of Massachusetts at Lowell, with graduate work in data visualization of genomics data, and Certificate of Management Excellence from Harvard Business School.